Corbus Pharmaceuticals Holdings (CRBP) Net Margin (2015 - 2021)

Corbus Pharmaceuticals Holdings' Net Margin history runs 7 years deep, the most recent figure standing at 54130.64% for Q3 2021.

• On a quarterly basis, Net Margin fell 4859241.0% year-over-year to 54130.64% in Q3 2021; TTM through Jun 2022 was 98105.61%, a 9288998.0% decrease from a year earlier, with the FY2021 full-year figure at 14912.83%, down 1243410.0% from the prior year.
• Net Margin eased to 54130.64% in Q3 2021 per CRBP's latest filing, from 39517.77% in the prior quarter.
• Across five years, Net Margin topped out at 95.2% in Q4 2019 and bottomed at 54130.64% in Q3 2021.
• The 5-year median for Net Margin is 3991.81% (2018), against an average of 9584.89%.
• Across the five-year window, Net Margin surged 884814 bps in 2019 and tumbled 4859241 bps in 2021, its largest moves.
• Year by year, Net Margin stood at 4639.19% in 2017, then tumbled by 89 bps to 8752.94% in 2018, then surged by 101 bps to 95.2% in 2019, then plunged by 1381 bps to 1219.16% in 2020, then plunged by 4340 bps to 54130.64% in 2021.
• Per Business Quant, the three latest CRBP Net Margin figures stand at 54130.64% (Q3 2021), 39517.77% (Q2 2021), and 7988.91% (Q1 2021).